Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
“The negative predictive value we want to be high, and the false positive rate we want to be low. None of those beat the radiologist reads in both of those categories,” says Robert S. Wang, MD.
Renal tumor pathology has evolved considerably, expanding from two main types of renal malignant tumors to over 20 distinct types. Diagnostic criteria have advanced from purely morphological features to include histochemistry, immunohistochemistry (IHC), and molecular genetics. The World ...
Renal cell carcinoma (RCC) is a significant oncological challenge due to its heterogeneous nature and limited treatment options. The PAX developmental gene family encodes nine highly conserved transcription factors that play crucial roles in embryonic development and organogenesis, which have ...
CBM-588 is under clinical development by Miyarisan Pharmaceutical and currently in Phase I for Metastatic Renal Cell Carcinoma.
As the second most common malignant tumor in the urinary system, renal cell carcinoma (RCC) is imperative to explore its early diagnostic markers and therapeutic targets. Numerous studies have shown that AURKB promotes tumor development by phosphorylating downstream substrates. However, the ...
Renal tumor pathology has evolved considerably, expanding from two main types of renal malignant tumors to over 20 distinct types. Diagnostic criteria have advanced from purely morphological features to include histochemistry, immunohistochemistry (IHC), and molecular genetics. The World ...
"The positive trends emerging from the ongoing phase 1 trial of BMC128, particularly in combination with nivolumab, underscore the transformative potential of microbiome-based therapeutics in oncology,” says Gal Markel, MD, PhD, MBA.
Palbociclib is under clinical development by Pfizer and currently in Phase II for Papillary Renal Cell Carcinoma.
More than 70 percent of Japanese renal cell carcinoma patients have a specific genetic mutation pattern that is rarely found in other countries, an international team of researchers said.
Sirolimus albumin-bound is under clinical development by Aadi Bioscience and currently in Phase II for Renal Cell Carcinoma.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.